CYTK Phase 3 readout: a positive outcome, +16.7%

On June 15, 2026, Aficamten — Cytokinetics, Incorporated (Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy) reached its Phase 3 readout. The result was a positive outcome, and the stock moved +16.7% in the window around the event. It had already run -5.1% in the 30 days into the catalyst — the kind of pre-event run-up that often precedes binary readouts.